Source:http://linkedlifedata.com/resource/pubmed/id/12100148
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2002-7-8
|
pubmed:abstractText |
Interleukin 6 (IL-6) is a potent immunomodulatory cytokine that has pathogenic and prognostic significance in a number of disorders. Previous studies in Hodgkin's disease (HD) have demonstrated the association between elevated serum levels of IL-6 and unfavourable prognosis, including advanced stage and the presence of 'B' symptoms and with reduced survival. Although IL-6 expression has been demonstrated in both the malignant Hodgkin/Reed-Sternberg (HRS) cells and in the various non-malignant cells present in HD biopsies, a relationship between expression of IL-6 by the tumour and outcome measures has not been established. The study group comprised of 97 patients with advanced HD who were recruited to two related clinical trials. IL-6 expression was determined on paraffin-wax sections of biopsy material by means of an immunohistochemical assay. Of the 97 patients, 27 (28%) showed staining for IL-6 in HRS cells. IL-6 expression by HRS cells was significantly correlated with a decreased likelihood of achieving a complete response to chemotherapy (P = 0.02) and with an increased prevalence of 'B' symptoms (P = 0.04). IL-6 expression by HRS cells was not associated with Epstein-Barr virus status (P = 0.57). In summary, the results suggest that IL-6 expression by HRS cells may contribute to the presence of 'B' symptoms and to a decreased likelihood to achieve a complete remission in HD patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0007-1048
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
118
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
195-201
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:12100148-Adult,
pubmed-meshheading:12100148-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12100148-Biological Markers,
pubmed-meshheading:12100148-Disease-Free Survival,
pubmed-meshheading:12100148-Epstein-Barr Virus Infections,
pubmed-meshheading:12100148-Female,
pubmed-meshheading:12100148-Hodgkin Disease,
pubmed-meshheading:12100148-Humans,
pubmed-meshheading:12100148-Immunohistochemistry,
pubmed-meshheading:12100148-Interleukin-6,
pubmed-meshheading:12100148-Male,
pubmed-meshheading:12100148-Middle Aged,
pubmed-meshheading:12100148-Prognosis,
pubmed-meshheading:12100148-Reed-Sternberg Cells,
pubmed-meshheading:12100148-Regression Analysis,
pubmed-meshheading:12100148-Remission Induction
|
pubmed:year |
2002
|
pubmed:articleTitle |
Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease.
|
pubmed:affiliation |
The Liver Research Laboratories, CRC Institute for Cancer Studies, Department of Pathology, University of Birmingham, Edgbaston, UK.
|
pubmed:publicationType |
Journal Article
|